論文

査読有り 国際誌
2020年4月

National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • Shinya Tsuzuki
  • ,
  • Nobuaki Matsunaga
  • ,
  • Koji Yahara
  • ,
  • Yoshiaki Gu
  • ,
  • Kayoko Hayakawa
  • ,
  • Aki Hirabayashi
  • ,
  • Toshiki Kajihara
  • ,
  • Motoyuki Sugai
  • ,
  • Keigo Shibayama
  • ,
  • Norio Ohmagari

26
4
開始ページ
367
終了ページ
371
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.jiac.2019.10.017

There has been scarce evidence about deaths due to blood stream infection (BSI) in Japan so far. The main objective of this study is to understand the epidemiological trend of deaths caused by BSIs due to Staphylococcus aureus and Escherichia coli including Methicillin-resistant S. aureus (MRSA) and fluoroquinolone-resistant E. coli (FQREC) at national level. We annually estimated the number of BSI caused by S. aureus and E. coli between 2011 and 2017 across Japan using comprehensive data of bacterial culturing and drug susceptibilities collected in Japan Nosocomial Infection Surveillance (JANIS). The number of death was estimated by using BSI mortality obtained from previous studies in Japan. The number of BSI death attributable to S. aureus was estimated to 17,412 in 2011 and 17,157 in 2017, respectively, out of the whole population (126.8 million) in Japan. Among them, cases attributed to MRSA accounted for 5924 (34.0%) in 2011, and decreased to 4224 (24.6%) cases in 2017. On the other hand, the number of BSI death attributable to E. coli was estimated to 9044 in 2011 and increased to 14,016 in 2017. Among them, cases attributed to FQREC accounted for 2045 (22.6%) in 2011 and increased to 3915 (27.9%) cases in 2017. The number of BSI death attributable to MRSA has been decreasing and that attributable to FQREC has been increasing. This study provides the first annual estimate of disease burden of BSI caused by antimicrobial resistant (AMR) bacteria in Japan, and basis for formulating health policy to deal with AMR.

リンク情報
DOI
https://doi.org/10.1016/j.jiac.2019.10.017
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31801696
ID情報
  • DOI : 10.1016/j.jiac.2019.10.017
  • PubMed ID : 31801696

エクスポート
BibTeX RIS